(11 May 2020) Hydroxychloroquine- not significantly associated with differences in in-hospital mortality

Association of Treatment With Hydroxychloroquine or Azithromycin
With In-Hospital Mortality in Patients With COVID-19 in New York State

https://jamanetwork.com/journals/jama/fullarticle/2766117

Among 1438 hospitalized patients with a diagnosis of COVID-19 (858 [59.7%] male, median age, 63 years), those receiving hydroxychloroquine, azithromycin, or both were more likely than those not receiving either drug to have diabetes, respiratory rate >22/min, abnormal chest imaging findings, O2 saturation lower than 90%, and aspartate aminotransferase greater than 40 U/L. Overall in-hospital mortality was 20.3% (95% CI, 18.2%-22.4%). The probability of death for patients receiving hydroxychloroquine azithromycin was 189/735 (25.7% ), hydroxychloroquine alone, 54/271 (19.9% ), azithromycin alone, 21/211 (10.0% ), and neither drug, 28/221 (12.7% ). Among patients hospitalized in metropolitan New York with
COVID-19, treatment with hydroxychloroquine, azithromycin, or both, compared with neither treatment, was not significantly associated with differences in in-hospital mortality. However, the interpretation of these findings may be limited by the observational design.